TiE2 is a receptor tyrosine kinase, and patients with PDAC with higher TiE2+ TAM frequencies have shown a greater risk of tumor development as a metastatic disease,195,196 whereas the TiE2 inhibitor rebastinib has been shown to be effective in reducing the growth and metastasis of pancreatic neuroendocrine tumors in mice.195. Here, TEK is linked to neoplasm.